title: Eosinophils in exercise-induced asthma.
abstract: The variations in serum levels of eosinophil cationic protein (ECP) have been measured after exercise challenge of 13 patients with asthma with exercise-induced asthma (EIA) and nine patients with asthma without EIA. The patients were treated before exercise in a randomized and blinded fashion with inhalation of one dose of either disodium chromoglycate, terbutaline, or budesonide and in an open study with 4 weeks of inhaled budesonide. In the group with EIA, there was, in some patients, an initial increase in serum levels of ECP after exercise, but 60 minutes after exercise, the levels were significantly reduced (p less than 0.001). Disodium chromoglycate and 4 weeks of budesonide treatment inhibited this reduction. Histamine challenge of the group with EIA produced a similar fall in serum ECP levels (p less than 0.001). The group without EIA had initially lower levels of ECP than the group with EIA (p less than 0.05 to p less than 0.01), and ECP stayed unaltered after exercise. The preexercise serum ECP levels correlated significantly to the maximal fall in peak expiratory flow in the untreated group (r = 0.91; p less than 0.001) and in the group receiving one dose of budesonide (r = 0.62; p less than 0.05). The blood eosinophil counts were unchanged after challenge and not related to lung function. The results suggest that the ECP content in serum reflects the degree of allergic inflammation in the lungs and thereby the degree of bronchial hyperreactivity.
authors.affiliation: Department of Clinical Chemistry, University Hospital, Uppsala, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Venge
authors.forename: J
authors.initials: J
authors.lastname: Henriksen
authors.forename: R
authors.initials: R
authors.lastname: Dahl
mesh_terms: D000293:Adolescent; D000328:Adult; D000336:Aerosols; D001250:Asthma, Exercise-Induced / Q000097:blood* / Q000188:drug therapy; D001798:Blood Proteins / Q000032:analysis; D019819:Budesonide; D004311:Double-Blind Method; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D010366:Peak Expiratory Flow Rate; D011282:Pregnenediones / Q000627:therapeutic use; D011897:Random Allocation; D012260:Ribonucleases; D013726:Terbutaline / Q000627:therapeutic use
chemical_list: D000336:Aerosols; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D011282:Pregnenediones; D019819:Budesonide; D012260:Ribonucleases; D013726:Terbutaline